Business
Aussie biotech Starpharma signs deal to sell COVID nose spray in Britain – Sydney Morning Herald
The Melbourne-based firm’s market value is approaching the billion-dollar mark amid rising investor interest in its COVID-preventative treatment.
Australian biotech Starpharma is taking its COVID-fighting antiviral nasal spray to the world, signing a deal with UK chemist chain LloydsPharmacy to sell the product in Britain as the country emerges from lockdown.
The Melbourne-based company announced a deal on Thursday morning that will see its Viraleze virus-fighting product sold online in the UK starting next week. It will also be stocked in Lloyds 1400-strong pharmacy network.
Chief executive Jackie Fairley declined to comment on the value…
-
Noosa News13 hours agoWoman dead and man rushed to hospital with gunshot wound following crash near Aussie World on Queensland’s Sunshine Coast
-
General19 hours agoBoy dies after being trapped between rocks off NSW beach
-
Noosa News20 hours agoFarmer Fred Perry’s 30-year conservation project creates bird haven after years of ‘bashing and burning’
-
Noosa News20 hours agoDetectives continue to search for answers on Crystal Beale’s death